Tralokinumab Safe for Special Atopic Dermatitis Populations

A recent retrospective study indicated that tralokinumab was linked with significant improvements in atopic dermatitis (AD) in special populations (SPs) such as the elderly and those with significant comorbidities.

Researchers investigating the efficacy and safety of tralokinumab in treating moderate-to-severe AD noted that these populations are typically excluded from clinical trials, making post-marketing data important. The cohort included individuals with various comorbid conditions such as cancer, neurological disorders, and cardiovascular disease. The authors conducted the analysis over 24 weeks and included 27 patients. Disease severity was assessed using the Eczema Area Severity Index (EASI), Pruritus–Numerical Rating Scale (P-NRS), and Dermatology Life Quality Index (DLQI).

According to the analysis, significant improvements were reported in all three metrics, with reductions in EASI and P-NRS scores beginning at week 4 and continuing through week 24. DLQI scores also decreased significantly at each timepoint. No adverse events were reported during the study period.

Despite the complexity of these cases, tralokinumab was well-tolerated.

"In our study, the effectiveness and safety of tralokinumab have been evaluated in elderly AD patients or patients affected by malignancies, severe neurological, psychiatric, pulmonary, and/or cardiovascular disease, and C hepatitis," the authors wrote in the study. "A statistically significant improvement was reported for each investigated score (EASI, P-NRS, DLQI) since week 4, continuing to improve up to week 24. Moreover, no AEs were collected. Despite promising, further observational data with more patients or longer follow-up periods are needed to confirm our results."

Source: Potestio L, et al. Journal of Asthma and Allergy. 2024. Doi:10.2147/JAA.S474411